By Adria Calatayud

AstraZeneca PLC said Tuesday that it will engage with shareholders after some resolutions put to vote at its annual general meeting received significant minority opposition.

The British pharmaceutical giant said its directors' remuneration policy was supported by 60.19% of votes cast at the meeting, while a proposal to amend the rules of its 2020 performance-share plan was backed by 61.72% of votes cast. A resolution to re-elect Sheri McCoy as a director received the support of 74.03% of the votes cast.

AstraZeneca said its board noted the lower of support received for these resolutions. The board has engaged with some shareholders to understand the reasoning behind their decision not to support the resolutions and will continue to do so during 2021, the company said.

Write to Adria Calatayud at adria.calatayud@dowjones.com

(END) Dow Jones Newswires

05-11-21 0927ET